热门资讯> 正文
诺和诺德因削减指导而面临股东诉讼
2025-08-05 01:37
- Novo Nordisk (NVO) is facing a shareholder lawsuit due to its recent decision to lower its full-year growth outlook for revenue and operating profit, citing headwinds in the GLP-1 market.
- ADRs of the weight loss drugmaker plunged over 20% on Tuesday in reaction to the decision, marking the stock’s sharpest intraday decline since 1987, according to Bloomberg data.
- A group of Novo (NVO) shareholders filed a proposed class action lawsuit in a federal court in New Jersey against the Danish firm on Friday, seeking to recover losses from an alleged securities fraud committed by the company between May 7 and July 28, 2025.
- The plaintiffs alleged that NVO issued exceedingly positive remarks and distributed false and misleading statements regarding its growth potential and hid materially significant adverse facts during that timeframe, creating shareholder losses as the stock plunged following the guidance cut.
More on Novo Nordisk
- Novo Nordisk Is Now A Better Value Play Than Eli Lilly With Solid Upside
- Novo Nordisk: I Was Wrong Twice, But This Selloff Looks Like 2016 All Over Again
- Novo Nordisk: Don't Miss Buying This Dip
- Noom launches microdose copies of Novo's Wegovy at $119
- Notable analyst calls this week: Nike, Microsoft and Sarepta among top picks
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
